Company
Headquarters: San Diego, CA, United States
Employees: 17
CEO: Dr. Brian Lian Ph.D.
$3.17 Billion
USD as of July 1, 2025
| Company | Market Cap (USD) | 
|---|---|
| Novo Nordisk | $309.91 B | 
| Vertex Pharmaceuticals Incorporated | $117.36 B | 
| CSL Limited | $95.75 B | 
| Regeneron Pharmaceuticals, Inc. | $59.14 B | 
| Marinomed Biotech AG | $58.56 B | 
| Company | Market Cap (USD) | 
|---|---|
| Lilly | $699.59 B | 
| Johnson & Johnson | $374.29 B | 
| AbbVie | $336.94 B | 
| Novo Nordisk | $309.91 B | 
| UnitedHealth Group | $279.90 B | 
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRà), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRà for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
| Last Financial Reports Date | March 31, 2025 | 
| Revenue TTM | $0 | 
| EBITDA | $0 | 
| Gross Profit TTM | $0 | 
| Profit Margin | 0.00% | 
| Operating Margin | 0.00% | 
| Quarterly Revenue Growth | % | 
Viking Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: VKTX wb_incandescent
Stock: FSX: 1VT wb_incandescent